Interferon-γ: 1,000,000 IU administered intravenously on Day 1 of each 3-week cycle for a total of 3-4 cycles.
Camrelizumab: 200 mg administered intravenously on Day 1 of each 3-week cycle for a total of 3-4 cycles.
Study summary
This study aims to evaluate the efficacy and safety of interferon-gamma combined with camrelizumab plus chemotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma. Based on previous mechanistic research and preliminary clinical data, this trial intends to generate high-level evidence for this therapeutic strategy, which may improve the treatment landscape for patients with locally advanced esophageal squamous cell carcinoma.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Aged \>= 18 years;
2. Histologically confirmed esophageal squamous cell carcinoma (ESCC), clinical stage cT1b-3, N+, M0;
3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
4. Expected overall survival \> 6 months;
5. Adequate bone marrow, hepatic, renal, coagulation, and thyroid function.
Exclusion Criteria:
1. Active autoimmune disease;
2. Requirement for systemic immunosuppressive therapy;
3. Hypersensitivity to any study drug;
4. Uncontrolled significant organ disease (e.g., cardiac, pulmonary, hepatic, renal) or active infection;
5. Pregnant or lactating female.
Primary outcome measure(s)
Pathological complete response rate — At the time of surgical resection. The proportion of patients achieving pathological complete response (absence of viable tumor cells in primary lesion and regional lymph nodes) evaluated by pathological examination of surgical specimens.
Trial sites (2)
Facility
City
Region
Status
Hefei Cancer Hospital, Chinese Academy of Sciences
Hefei
Anhui
Recruiting
The First Affiliated Hospital of Anhui Medical University
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.